Sanofi Consumer Healthcare India Limited (SANOFICONR) Q2 2026 earnings summary

Executive summary

• Revenue for Q2 2026 reached ₹2,357 million, up 7% year-over-year, with domestic sales growing 12% and export sales declining 9% on a high base.

• Net profit for Q2 2026 was ₹919 million, with profit before tax up 16% year-over-year.

• For the half year ended June 30, 2026, revenue from operations was ₹4,649 million, up 18% year-over-year, with domestic sales up 14% and export sales up 27% on a low base.

• Profit before tax for the half year increased by 25% year-over-year.

Financial highlights

• Cash and cash equivalents increased to ₹4,902 million as of June 30, 2026, from ₹3,748 million at December 31, 2025.

• Net cash inflow from operating activities for H1 2026 was ₹1,096 million, compared to ₹179 million in H1 2025.

• Net cash used in financing activities was ₹47 million for H1 2026, significantly lower than the ₹1,298 million outflow in H1 2025.

Outlook and guidance

• Management highlighted disciplined execution and targeted investments as drivers of profitable growth and market share gains.

• The company remains confident in its strategy and continues to focus on strengthening its brand portfolio.